| New from NCI |
| MyPART–My Pediatric and Adult Rare Tumor Network |
 |
|
MyPART is a program that engages patients, advocates, and researchers to improve the lives of people with rare cancers. Learn about specific rare tumors, rare tumor workshops and clinics, and how to take part in a natural history study. |
| NCI’s Rare Cancer Clinics: Engaging Patients and Fostering Collaboration |
 |
|
NCI has created special clinics that bring together clinicians, patients, and advocates to promote more rapid progress against rare cancers. The effort includes both rare pediatric cancers and central nervous system tumors in adults. |
Trial Compares E-Cigarettes and Nicotine-Replacement Products for Quitting Smoking
Results from a study in the United Kingdom suggests that smokers who used e-cigarettes and smoking cessation counseling had higher quit rates than smokers who used nicotine replacement therapies and counseling. |
Eliminating Racial Disparities in Early-Stage Lung Cancer Treatment
In a new study, a three-part approach closed the treatment gap between black and white patients with early-stage lung cancer. |
| Making Cancer Clinical Trials Available to More Patients |
 |
|
Eligibility criteria are necessary to ensure that clincal trials compare similar groups of patients, but they can be a barrier to trial participation. Read about efforts by NCI to broaden eligibility for clinical trials while still maintaining patient safety. |
Selected Interviews with the NCI Director
Watch and listen to interviews with Dr. Ned Sharpless during his time as NCI director, including the recent ASCO in Action Podcast, which addressed big data, clinical trials, and the cancer research workforce.
|
| PDQ Summary Updates |
Childhood Central Nervous System (CNS) Germ Cell Tumors Treatment
We revised our PDQ summary on childhood CNS germ cell tumors with updated descriptions of the different types of CNS germ cell tumors and the treatment options for newly diagnosed and recurrent disease.
|
| Drug Information Updates |
Talazoparib Tosylate
We've added a new drug summary for talazoparib tosylate (Talzenna). It was approved by the Food and Drug Administration to treat breast cancer that is HER2 negative and has certain germline mutations in the BRCA1 or BRCA2 gene. |
